TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Evaluating the Efficiency of Holmium Laser Settings on Urinary Stones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years of age~* Patients with urinary stones who require endoscopic treatment~Exclusion Criteria:~* Patients \< 18 years of age~* Pregnant patients~* Pre-menopausal females who have not been on approved birth control for at least 1 month pre-operatively~* Patients with stones known to be refractory to treatment with the holmium laser

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Holmium:YAG laser: 0.2J&15Hz (Type: ACTIVE_COMPARATOR): Patients are assigned to treat stones with 0.2J\&15Hz of the holmium laser.
- Holmium:YAG laser: 0.8J&15Hz (Type: EXPERIMENTAL): Patients are assigned to treat stones with 0.8J\&15Hz of the holmium laser.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 6 months~* Treated with maximal, tolerable dose of metformin (≥ 1000mg/day) and sulfonylurea (glimepiride≥ 4 mg/day or equivalent dose of other SU) for at least 3 months prior to the screening visit~* 7.0 \< HbA1c \< 11 %~* Fasting serum C-peptide \> 0.33 nmol/L~* BMI \< 30 kg/m²~* Patients who is willing to monitor BG using SMBG~Exclusion Criteria:~* Type 1 Diabetes~* Clinical evidence of active liver disease, or serum ALT 3 times the upper limit of the normal range~* Serum creatinine: ≥ 1.5 mg/dl for males, ≥ 1.4 mg/dl for females~* Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)~* History of alcohol or other substance abuse~* Pregnancy or not using contraceptive in childbearing aged women~* Breast feeding women~* History of hypersensitivity to the study drugs or to drugs with a similar chemical structure~* Treatment with any medication including corticosteroid or herbal medicines that can affect blood glucose level within 3 months prior to study entry except metformin and sulfonylurea.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Administration of 4 mg of Glimepiride with Insulin Glargine
- 2 (Type: ACTIVE_COMPARATOR): Administration of 1500 mg of Metformin with Insulin Glargine
- 3 (Type: EXPERIMENTAL): Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Histologically or cytologically confirmed malignant disease~3. Accept chemotherapy for the first time~4. Patients who will receive high emetogenic cancer chemotherapy (HEC) (cisplatin\>=70mg/m2,adriamycin in combination with cyclophosphamide ,cyclophosphamide\>=1500mg/m2,adriamycin\>60mg/m2,epirubicin\>90mg/m2,dacarbazine，ifosfamide\>=2g/m2) or moderate emetogenic chemotherapy cancer (carboplatin\>=300mg/m2,cyclophosphamide\>=600-1000mg/m2,adriamycin\>50mg/m2)~5. Written informed consent~Exclusion Criteria:~1. Pregnant or breast-feeding~2. Uncontrolled psychosis history~3. Inability or unwillingness to understand or cooperate with study procedures~4. Central nervous system tumors primary or secondary~5. Concurrent abdominal radiotherapy~6. History of uncontrolled diabetes mellitus~7. Patients of prostatic hyperplasia ，paralytic ileus，narrow feet glaucoma.~8. Known cardiac arrhythmia, uncontrolled congestive heart failure ,or acute myocardial infarction with the previous six month~9. Pre-existing nausea or vomiting~10. Inadequate hematological function and abnormal liver and renal function.~11. History of sensitivity to olanzapine~12. Concurrent application of quinolone antibiotic therapy~13. Treatment with another antipsychotic agent such as risperidone,quetiapine, clozapine,phenothiazine,or butyrophenone for 30 days prior to or during the chemotherapy.~14. Cytochrome P450 3A4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide)~15. Concurrent application of systemic corticosteroids~16. Active infection or gastrointestinal dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olanzapine regimen (Type: EXPERIMENTAL): Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
- Control regimen (Type: OTHER): Aprepitant in combination with palonosetron and dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed as recurrent disease or stage IV~* has at least 1 measurable lesion by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1~Exclusion Criteria:~* has predominantly squamous cell histology non-small cell lung cancer~* had surgery for metastatic nsNSCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P16 (Type: EXPERIMENTAL): Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
- Avastin (Type: ACTIVE_COMPARATOR): Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Non-Hodgkin's Lymphoma (B- or T-cell) or Hodgkin's lymphoma.~2. Prior Chemotherapy\</= 4 weeks of treatment.~3. Age \>/= 18 years old.~4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3.~5. Estimated creatinine clearance \>/= 60 ml/min.~6. Must sign an informed consent form.~Exclusion Criteria:~1. Radiologic evidence of vertebral or hip fracture.~2. BMD T-score less than (i.e., worse than or more negative than) -2.0 at any of the following sites: lumbar spine, femoral neck, or total hip.~3. Patients with secondary non-lymphomatous cancers metastatic to bone. However, other secondary cancers are allowed.~4. Spinal cord compression due to vertebral collapse.~5. Bisphosphonate treatment in the prior 6 months or steroid use (greater than 35 mg of prednisone equivalent steroids) in the prior 3 months. The use of topical, inhaled, or nasal steroids is allowed.~6. Primary hyperparathyroidism.~7. Active osteomalacia.~8. Untreated hypocalcemia (ionized, iCa), Ionized Ca level must be within normal limits prior to enrollment.~9. Untreated secondary hyperparathyroidism, Patients with abnormal parathyroid hormone (PTH) levels may be enrolled as long as they are being treated.~10. Untreated vitamin D deficiency, Vitamin D level may be abnormal and patient may be enrolled as long as they are being treated.~11. Untreated low testosterone (test in men only), testosterone level may be abnormal and patient may be enrolled as long as they are being treated.~12. Paget's disease.~13. Pregnant or breast-feeding.~14. Radiotherapy involving the mandible.~15. Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), or of exposed bone in the mouth, or of slow healing after dental procedures.~16. Recent (within 3 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).~17. Patients with abnormal renal function as evidenced by either a serum creatinine greater than 3 mg/dL or by a calculated creatinine clearance of \< 60 mL/minute.~18. Known hypersensitivity to zoledronic acid or other bisphosphonates.~19. Hypercalcemia: corrected Ca \> 10.2 mg/dL or ionized Ca \> 1.32 mmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D + Calcium Carbonate (Type: EXPERIMENTAL): Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
- Vitamin D + Calcium Carbonate + Zoledronic Acid (Type: EXPERIMENTAL): Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m\^2 intravenous at baseline and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has been postmenopausal for 3 years~* Participant has BMD t-score at the total hip, hip trochanter, femoral neck, or lumbar spine ≥ -1.5 but \> -3.5~* Participant has 2 hips that are evaluable by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), e.g. contain no hardware from orthopedic procedures~* Participant is ambulatory~Exclusion Criteria:~* Participant has had a previous hip fracture~* Participant has had \>1 prior clinical vertebral fracture AND is a candidate for osteoporosis therapy~* Participant has been treated with oral bisphosphonates, strontium, parathyroid hormone (PTH) or other agents with an effect on bone~* Participant has had metabolic bone disorder other than osteoporosis~* Participant has renal stones, Parkinson's disease, multiple sclerosis (MS) or active parathyroid disease.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Odanacatib 50 mg (Type: EXPERIMENTAL): Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children of either sexes, aged 0-12 years~* Diagnosis of mono- or bilateral primary congenital glaucoma~* IOP greater than or equal to 22 mmHg and lower than 27 mmHg~* Only one previous ocular hypotensive surgical procedure for treatment of glaucoma among the following: goniotomy, trabeculotomy, trabeculotomy with adjunct of mitomycin C) (only for medical treatment at least one month before)~* Parent informed consent to data processing (at registration)~* Parent informed consent before any study procedure~Exclusion Criteria:~* Secondary glaucoma (Sturge-Weber syndrome, type I neurofibromatosis, retinoblastoma, steroid-induced glaucoma, etc.)~* Presence of concomitant abnormalities of the anterior segment of the eye (cataract, iridocorneal dysgenesia, congenital uveal ectropion uvea, etc.)~* Previous treatment with the study drugs~* Presence of concomitant systemic diseases (asthma, hypertension, cardiac disease, renal failure, etc.) that needs treatment with drugs, that could influence IOP (steroids, beta-blockers, angiotensin-converting-enzyme inhibitor -inhibitors diuretics, etc.)~* Abnormalities of the cornea that could influence IOP readings (marked cornea edema)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Latanoprost, Dorzolamide (Type: OTHER): According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV Persistence and Viral Reservoirs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years, and~2. HIV infection, and~3. Antiretroviral-naïve, and~4. CD4+ T cell count \>350 cells/mm3, and~5. Controllers: antiretroviral untreated with 50-1000 copies/mL viral load for at least 12 months~Exclusion criteria:~1. Persons with known rheumatologic conditions (e.g., systemic lupus erythematosus), because of their predilection for biologic false-positive testing on HIV antibody tests.~2. Screening absolute neutrophil count \<1,000 cells/mm3, platelet count \<70,000 cells/mm3, hemoglobin \< 8 mg/dL, estimated creatinine clearance \<40 mL/minute, aspartate aminotransferase \>100 units/L, alanine aminotransferase \>100 units/L.~3. Screening genotype resistance testing showing resistance to tenofovir or emtricitabine.~4. Known kidney disease.~5. Known bone disease, including pathologic fractures.~6. Patients with chronic Hepatitis B infection, because of the risk of liver abnormalities after starting and stopping tenofovir/emtricitabine.~7. Concurrent treatment with lamivudine, adefovir, entecavir, or telbivudine.~8. Serious illness requiring hospitalization or parental antibiotics within the preceding 3 months.~9. Any vaccination 2 weeks prior to baseline (Day 0) visit and throughout the study period. NOTE: Because the study will most likely be actively recruiting during the influenza season, all subjects will be encouraged to receive their annual influenza vaccine at the screening visit (4 weeks prior to baseline \[Day 0\] visit) if they have not already been vaccinated for the 2009-10 season and if it is medically indicated.~10. Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drug in the preceding 16 weeks (e.g. corticosteroid therapy equal to or exceeding a dose of 15 mg/day of prednisone for more than 10 days, IL-2, interferon-alpha, methotrexate, cancer chemotherapy). NOTE: Use of inhaled or nasal steroid use is not exclusionary.~11. Concurrent treatment with phenobarbital, phenytoin, or rifampin.~12. Pregnant or breastfeeding women. Females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Elite controller (Type: EXPERIMENTAL): Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential~* Patients with newly diagnosed sputum smear-positive pulmonary MDR-TB infection~* Patients must consent to HIV-testing~* Patients must be willing to discontinue all TB drugs to allow 7 days washout~* Patients having normal weight~* Patients are willing to be hospitalized per standard of care.~Exclusion Criteria:~* Previously having been treated for MDR-TB~* Having a significant cardiac arrhythmia that requires medication~* For HIV infected patients, having a CD4+ count \< 300 cells/µL~* Patients with complicated or severe extrapulmonary manifestations of TB or neurological manifestations of TB~* Patients who will require surgical procedure for management of their TB~* Evidence of chorioretinitis, optic neuritis, or uveitis at screening~* Having had a drug susceptibility test performed prior to screening and being not susceptible to at least 3 of the 5 classes of TB drugs used to treat MDR-TB~* Women who are pregnant and/or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TMC207 Stage 1 (Type: EXPERIMENTAL): TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
- Placebo Stage 1 (Type: PLACEBO_COMPARATOR): Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
- TMC207 Stage 2 (Type: EXPERIMENTAL): TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
- Placebo Stage 2 (Type: PLACEBO_COMPARATOR): Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Beta-Blocker Evaluation in Survival Trial (BEST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Men and women, ages 18 and over. Patients had compensated congestive heart failure due to idiopathic dilated cardiomyopathy or coronary disease with ejection fraction less than or equal to 0.35, were in the New York Heart Association functional class III or IV, and were taking an angiotensin-converting enzyme inhibitor, digitalis, and if needed, a diuretic. Patients with a specific indication for, or contraindication to, beta-blockade were excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Obese or severely obese.~* Initiated an OAC from July 1, 2013 - December 31, 2017; the first DOAC pharmacy claim date during the identification period will be designated as the index date. The first warfarin prescription date will be designated as the index date for patients without any DOAC claim.~* Individuals ≥18 years old as of the index date.~* Had 6 months continuous health plan enrollment with medical benefits (Parts A \& B) for at least 6 months pre-index date (baseline period).~* At least 1 diagnosis of AF prior to or on index date, identified by any medical claim associated with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 427.31 or International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code of I480-I482, and I4891.~* Had body weight or BMI value reported within ±6 months of the index date.~Exclusion Criteria:~* Had medical claims indicating a diagnosis or procedure of rheumatic mitral valvular heart disease, heart valve replacement/transplant, venous thromboembolism, or transient AF 6 months prior to or on the index date.~* Had hip/knee replacement surgery within 6 weeks prior to or on the index date.~* Were pregnant during the study period.~* Had an OAC prescription during the 6 months pre-index date.~* Had follow-up time equal to 0 days.~* Had more than one OAC on the index date.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban Group (Type: None): The cohort prescribed apixaban and diagnosed with Atrial Fibrillation
- Warfarin Group (Type: None): patients prescribed warfarin only diagnosed with Atrial Fibrillation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete